VIR closes $240M Astellas deal, raises $162M equity, advances ECLIPSE trials; CMO departs

Filed May 7, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 8, 2025 · ~1 min read

Key Changes

• high

  Closed Astellas collaboration for VIR-5500 prostate cancer asset with $240M upfront plus $75M equity investment, positioning for 2027 pivotal trials and potential commercialization partnership.

  MD&A: Astellas collaboration verify on EDGAR →
• high

  ECLIPSE Phase 3 CHD trials on track: topline data expected Q4 2026 (ECLIPSE 1) and Q1 2027 (ECLIPSE 2/3), representing company's most critical near-term regulatory catalyst.

  MD&A: ECLIPSE timeline verify on EDGAR →
• high

  Raised $162M net in February 2026 follow-on offering but cash declined $211M year-over-year to $809M despite raise, reflecting elevated burn rate from ECLIPSE and oncology programs.

  MD&A: Cash position verify on EDGAR →